SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
AMGN Analysis & Videos »
AMGN: Bull or Bear?
YM BioSciences: Trading Below Cash with Multiple Catalysts
AMGN
|
|
|
-9.22%
in
94 days
YM BioSciences (AMEX:YMI) (TSE:YM) (US$0.58) currently trades at a negative enterprise value of about $10 million (M), which includes $43M in cash, zero debt, and a trailing 12-month cash burn rate of about $18M. YMI has about 58.5M shares outstanding and 65M shares of common stock on a fully diluted basis, which equates to a market cap of about US$34M and US$38M, respectively. <o:p> </o:p> http://biomedreports.com/articles/most-popular/5071-ym-biosci... <o:p> </o:p> <> Nimotuzumab (nimo) (an IgG1, humanized epidermal growth factor or EGFR targeting mo...
|
FDA Calendar Updates: Acorda, Amgen, DOR BioPharma
AMGN
|
|
|
-4.77%
in
4 days
(closed on 08/08/09)
Below is a summary of updates to the BioMedReports.com FDA Calendar , which includes a database of 290 entries as of 8/4/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of BioMedReports.com, the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, ANDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending late-stage clinical trial result...
|
Amgen 2Q Earnings Beat, Raises Guidance, Denosumab Deal
AMGN
|
|
|
+4.53%
in
8 days
(closed on 08/04/09)
Amgen (NASDAQ:AMGN) reported adjusted earnings per share (EPS) of $1.29 for 2Q09, an increase of 13% compared to $1.14 for the 2Q08. Adjusted net income increased 6% to $1.3 billion during 2Q09 versus $1.2 billion during 2Q08. Total revenue declined by 1% during 2Q09 to $3.71 billion versus $3.76 billion during 2Q08. The Company provided revenue guidance for 2009 that is trending towards the upper end of its current guidance range of $14.4-14.8 billion. Amgen now expects 2009 adjusted EPS to be in the range of $4.80-4.95, an increase from the previous range of $4.55 to $4.75. The Company no...
|
FDA Calendar: 2H09 Binary Event Trades
AMGN
|
|
|
-0.25%
in
1 day
(closed on 07/27/09)
<> Below is a selection of companies included in the BioMedReports.com FDA Calendar database of 281 entries as of 7/26/09 with expected binary event catalysts through year-end. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of BioMedReports.com , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the ...
|
FDA Calendar Updates: Amgen, Bayer, Biogen, Noveko, Peplin, Transdel
AMGN
|
|
|
+0.63%
in
18 days
(closed on 07/26/09)
<> Below is a summary of updates to the <font> BioMedReports.com FDA Calendar </font> , which includes a database of 246 entries as of 7/8/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending...
|
FDA Calendar Updates: EURX, AMGN, FOLD, ONTY, MEDX
AMGN
|
|
|
+18.73%
in
16 days
(closed on 07/08/09)
<> Below is a summary of updates to the <font> BioMedReports.com FDA Calendar </font> , which includes a database of over 200 entries. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending late-st...
|
New Index of Highly Defensive Market Cap Leaders
AMGN
|
|
|
-9.19%
in
117 days
(closed on 06/22/09)
The ETF Innovators Highly Defensive Index contains 40 market cap leading companies which are based in either North America or Europe from the defensive industry groups (A-K) specified below. www.BioMedReports.com - Mike Havrilla (A) Mass Merchant Discount Retailer (1): Wal-Mart (WMT) <> <> (B) Consumer Staples (12): Coca-Cola (KO), Colgate-Palmolive (CL), Diageo (DEO), General Mills (GIS), Danone (GDNNY), Kraft Foods (KFT), Nestle (NSRGY), PepsiCo (PEP), Philip Morris International (PM), Procter & Gamble (PG), Reckitt Benckiser (RBGPF), Unilever (UN) <><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><>< />...
|
Bullish on AMGN ...
AMGN
|
|
|
+0.00%
in
1 minute
(closed on 02/25/09)
New Index of Highly Defensive Market Cap Leaders The ETF Innovators Highly Defensive Index contains 40 market cap leading companies which are based in either North America or Europe from the defensive industry groups (A-K) specified below. www.BioMedReports.com - Mike Havrilla (A) Mass Merchant Discount Retailer (1): Wal-Mart (WMT) <> <> (B) Consumer Staples (12): Coca-Cola (KO), Colgate-Palmolive (CL), Diageo (DEO), General Mills (GIS), Danone (GDNNY), Kraft Foods (KFT), Nestle (NSRGY), PepsiCo (PEP), Philip Morris International (PM), Pro<><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><>< />...
|
Create Your Own Highly Defensive ETF
AMGN
|
|
|
+2.58%
in
35 days
(closed on 02/25/09)
Create Your Own Highly Defensive ETF The table at my website link below contains 35 companies included in the ETF Innovators [ETFI] Highly Defensive PerformIdex which are based in the U.S., Canada, and Europe with market caps over $10B that are the leaders by market cap in their defensive industry groups. The index includes 23 consumer staples and healthcare companies, with the remaining 12 companies chosen from a variety of other defensive industry groups. <> (A) Mass Merchant Dis...
|
A New Index of Health Product Innovators
AMGN
|
|
|
-7.57%
in
16 days
(closed on 01/21/09)
<> 
The accompanying table includes statistics and all 23 companies in the ETF Innovators [ETFI] Global Health Innovators Index of companies with market caps over $250M which received FDA approval in the past 12 months for an original new drug product or medical device.
The index includes companies which get approvals for drugs or biological agents classified as new chemical entities (i.e. excluding all new formulations of existing drugs, generic drugs, and label extensions for existing products). Also, companies whi...
|
Four Healthy Stocks Trading Above Moving Averages
AMGN
|
|
|
+2.65%
in
4 days
(closed on 01/05/09)
Amgen (AMGN), AspenBio Pharma (APPY), BioDelivery Sciences (BDSI), and Cypress Bioscience (CYPB) are four healthcare stocks that I follow which are poised to close out a rough 2008 for the overall market trading above their 50 and 200-day moving averages, in addition to having significant catalysts in 2009 which may lead to further gains. Below is a summary of the 2009 catalysts for these companies and click on the names or tickers below for a link to all of the articles on my blog for each stock: <> Amgen filed a BLA for bone drug denosumab in the following two indicatio...
|
A New Index of Highly Defensive Stocks
AMGN
|
|
|
+0.58%
in
2 days
(closed on 12/31/08)
<> The table at my website link below includes an update for the ETF Innovators [ETFI] Highly Defensive PerformIdex of 36 companies based in the <st1:country-region> <st1:place> U.S. </st1:place> </st1:country-region> , <st1:country-region> <st1:place> Canada </st1:place> </st1:country-region> , and <st1:place> Europe </st1:place> with market caps over $10B, which are the leaders by market cap in their defensive industry groups. The 36 companies are dominated by consumer staples and healthcare, with an equal distribution of 12 each from these sectors, with the remaining 12 compan...
|
FDA Calendar: High Hopes for Amgen's Bone Drug
AMGN
|
|
|
-1.39%
in
9 days
(closed on 12/29/08)
<> 
The accompanying table [click to enlarge] includes an updated FDA calendar of 69 expected decision dates included in the ETF Innovators [ETFI] New Drug Regulatory Catalyst Index, with seven companies listed in red with overdue decisions. Since my last update , the following FDA action has occurred:
1.) Amgen (AMGN) filed a BLA for bone drug denosumab in the following two indications: the treatment + prevention of osteoporosis in post-menopausal women and the treatment + prevention of bone loss in patient...
|
R&D Leads to Higher Returns for Top 20 Health Innovators
AMGN
|
|
|
+4.55%
in
27 days
(closed on 12/20/08)
<> 
<> The accompanying table includes statistics and the top 20 rated companies in the ETF Innovators [ETFI] Global Health Innovators Index of companies with market caps over $250M which received FDA approval in the trailing 12-month period for either an original new drug product or medical device. The index includes companies which get approvals for drugs or biological agents classified as new chemical entities (i.e. excluding reformulations of existing drugs, generic drugs, and label extensions for exist...
|
People Bullish on AMGN
People Bearish on AMGN
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on AMGN |
Portfolio results thru 8/8/08
- Portfolio at www.updown.com - started 1/11/08
9.8% return includes dividends and commission.
Started socialpicks on 6/30. some stocks here are not in...
|
Stock update and watch list 7/29/08
- Due to difficulties understanding the socialpicks system regarding changing rating from buy to hold and thus resetting the performance, I wanted to sum...
|
More Resources
|
About Amgen Inc
- Answers.com
There were a few stocks in 2008 that exhibited great performance despite horrible market conditions. And these gems of 2008 may provide investors with a safe haven of sorts for 2009. 
